Luspatercept
Contents
Description
Luspatercept is a recombinant fusion protein that acts as an erythroid maturation agent by binding to select TGF-beta superfamily ligands. It promotes late-stage erythropoiesis and reduces transfusion burden in patients with beta-thalassemia including hemoglobin E-beta-thalassemia syndrome. The drug enhances red blood cell maturation and production.
Indications & Therapeutic Use
beta-thalassemia, hemoglobin E-beta-thalassemia syndrome, myelodysplastic syndromes with ring sideroblasts
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Luspatercept — GNH India
6 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Luspatercept products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | luspatercept |
| Brands | 1 brand available |
| Active Ingredient | luspatercept-aamt |
| Drug Class | beta-thalassemia |
| Manufacturer | Bristol Myers Squibb/Celgene |
| Dosage Forms | subcutaneous injection, 25 mg/vial, 75 mg/vial powder for solution |
| Medical Code | B03XA05 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT02604433 |
| Countries | 8 countries |